AR040588A1 - Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa - Google Patents

Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa

Info

Publication number
AR040588A1
AR040588A1 AR20030102560A ARP030102560A AR040588A1 AR 040588 A1 AR040588 A1 AR 040588A1 AR 20030102560 A AR20030102560 A AR 20030102560A AR P030102560 A ARP030102560 A AR P030102560A AR 040588 A1 AR040588 A1 AR 040588A1
Authority
AR
Argentina
Prior art keywords
inhibitor
cholesterol absorption
hmgco
reductase
pharmaceutical formulation
Prior art date
Application number
AR20030102560A
Other languages
English (en)
Original Assignee
Schering Corp
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188454&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR040588(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp, Merck Sharp & Dohme filed Critical Schering Corp
Publication of AR040588A1 publication Critical patent/AR040588A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Composición farmacéutica que comprende un inhibidor de la absorción de colesterol y un inhibidor de una HMG-CoA reductasa, uno o más antioxidantes, celulosa microcristalina, hidroxipropil metilcelulosa, estearato de magnesio y lactosa. La composición no necesita contener ácido ascórbico en orden de obtener la estabilidad deseable. Reivindicación 1: Composición farmacéutica que comprende desde el 1% al 20% en peso de ezetimibe; desde el 1% al 80% en peso de simvastatin; y desde el 0,01% al 2% en peso de BHA.
AR20030102560A 2002-07-26 2003-07-16 Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa AR040588A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39869102P 2002-07-26 2002-07-26

Publications (1)

Publication Number Publication Date
AR040588A1 true AR040588A1 (es) 2005-04-13

Family

ID=31188454

Family Applications (2)

Application Number Title Priority Date Filing Date
AR20030102560A AR040588A1 (es) 2002-07-26 2003-07-16 Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
ARP080102576A AR067030A2 (es) 2002-07-26 2008-06-17 Composiciones farmaceuticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP080102576A AR067030A2 (es) 2002-07-26 2008-06-17 Composiciones farmaceuticas

Country Status (39)

Country Link
US (4) US7229982B2 (es)
EP (2) EP1531805B1 (es)
JP (2) JP2005538104A (es)
KR (2) KR20080070089A (es)
CN (2) CN1310643C (es)
AR (2) AR040588A1 (es)
AT (1) ATE393628T1 (es)
AU (2) AU2003261217B2 (es)
BR (1) BR0312933A (es)
CA (1) CA2493076A1 (es)
CR (1) CR9767A (es)
DE (1) DE60320652T2 (es)
DK (1) DK1531805T3 (es)
EA (1) EA008888B1 (es)
EC (2) ECSP055573A (es)
ES (1) ES2303603T3 (es)
GE (1) GEP20084443B (es)
GT (2) GT200300149A (es)
HK (1) HK1080384A1 (es)
HR (2) HRP20050081A2 (es)
IL (2) IL166279A0 (es)
IS (1) IS7637A (es)
MA (1) MA27289A1 (es)
ME (3) MEP4708A (es)
MX (1) MXPA05001004A (es)
MY (1) MY148689A (es)
NO (2) NO20051033L (es)
NZ (1) NZ537611A (es)
PA (1) PA8577901A1 (es)
PE (1) PE20050128A1 (es)
PL (1) PL375065A1 (es)
PT (1) PT1531805E (es)
RS (2) RS50419B (es)
SI (1) SI1531805T1 (es)
TN (1) TNSN05022A1 (es)
TW (2) TW200412944A (es)
UA (1) UA82489C2 (es)
WO (1) WO2004010993A1 (es)
ZA (1) ZA200500196B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2005047248A1 (en) * 2003-11-10 2005-05-26 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-ones
ATE485267T1 (de) 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
EP1905424A3 (en) * 2006-02-02 2008-04-30 Ranbaxy Laboratories Limited Process for the preparation of a pharmaceutical composition comprising stabilized statin particles
US20070275075A1 (en) * 2006-03-06 2007-11-29 Ilan Zalit Ezetimibe compositions
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
CN101677963B (zh) 2006-06-19 2012-05-30 奥尔制药公司 药物组合物
CN1994296B (zh) * 2006-08-02 2010-06-16 浙江京新药业股份有限公司 一种含有辛伐他汀的药物制剂
GB0713707D0 (en) 2007-07-13 2007-08-22 Generics Uk Ltd Stable compositions
CA2694378A1 (en) * 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
WO2009024889A2 (en) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
CN101938995A (zh) * 2007-12-17 2011-01-05 克卡制药新梅斯托股份公司 包含非微粉化依泽替米贝微粒的悬浮液
US20090233898A1 (en) * 2008-03-11 2009-09-17 Glenmark Generics Ltd Pharmaceutical Compositions Comprising Simvastatin and Ezetimibe
TR200806302A2 (tr) * 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite artırıcı farmasötik formülasyon.
EP2168573A1 (en) * 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
EP2204170A1 (en) * 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
WO2010066687A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Stabalized statin-comprising compositions
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
EP2448919A2 (en) * 2009-07-02 2012-05-09 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
WO2011002422A2 (en) * 2009-07-02 2011-01-06 Bilgic Mahmut Solubility enhancing pharmaceutical formulation
WO2011002424A2 (en) * 2009-07-02 2011-01-06 Bilgic Mahmut Solubility and stability enchancing pharmaceutical formulation
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
KR101302243B1 (ko) * 2010-07-28 2013-09-02 씨제이제일제당 (주) 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물
CN101978953A (zh) * 2010-10-11 2011-02-23 上海交通大学 基于易吸湿性辅料的固体制剂
EP2468258A1 (en) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
JP2014504630A (ja) 2011-02-02 2014-02-24 アルファーマ ファーマシューティカルズ エルエルシー オピオイドアゴニストおよび隔離されているアンタゴニストを含む医薬組成物
CN102266323B (zh) * 2011-08-04 2013-03-27 海南锦瑞制药股份有限公司 依折麦布和辛伐他汀组合物及其制备方法
US9592296B2 (en) 2011-09-08 2017-03-14 Hexal Ag Pharmaceutical composition for oral administration with a statin
WO2013166114A1 (en) * 2012-05-01 2013-11-07 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of atorvastatin and ezetimibe
DK2844233T3 (da) * 2012-05-01 2020-07-13 Althera Life Sciences Llc Oral tabletformulering bestående af en fastsat kombination af rosuvastatin og ezetimib til behandling af hyperlipidæmi og kardiovaskulære sygdomme
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
CN103585146B (zh) * 2013-11-09 2015-04-01 北京中申专利科技有限公司 辛伐他汀的药物组合物
TWI586380B (zh) * 2013-12-18 2017-06-11 夢製藥公司 包含ＨＭＧ－ＣｏＡ還原酶抑制劑及膽固醇吸收抑制劑之醫藥組合製劑
CN104306348B (zh) * 2014-09-30 2017-05-31 地奥集团成都药业股份有限公司 一种辛伐他汀片及其制备方法
CN108366957A (zh) * 2015-11-06 2018-08-03 燿石治疗公司 用于治疗心血管疾病的吉卡宾组合
CN106937952A (zh) * 2016-01-04 2017-07-11 重庆华邦制药有限公司 依折麦布和辛伐他汀的制剂
EP3281649A1 (en) * 2016-08-09 2018-02-14 Teleflex Lifesciences Wetting agent formulation
JP6937195B2 (ja) * 2017-09-01 2021-09-22 興和株式会社 医薬組成物
US11622939B2 (en) * 2017-11-23 2023-04-11 Zhejiang Hisun Pharmaceutical Co., Ltd. HS-25 tablet and preparation method therefor
US11833133B2 (en) * 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition
TWI760067B (zh) * 2020-08-13 2022-04-01 友霖生技醫藥股份有限公司 固態口服醫藥組成物
CN112168801A (zh) * 2020-10-22 2021-01-05 哈药集团技术中心 一种辛伐他汀片的制备方法
CN115227659B (zh) * 2022-08-19 2023-05-02 北京百奥药业有限责任公司 一种依折麦布辛伐他汀组合物及其制备方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
AU1422388A (en) 1987-01-27 1988-08-10 Warner-Lambert Company Lipid regulating compositions
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US4916239A (en) 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
ES2107548T3 (es) 1991-07-23 1997-12-01 Schering Corp Compuestos de beta-lactama sustituidos utiles como agentes hipocolesterolemicos y procedimientos para su preparacion.
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
NZ245514A (en) * 1991-12-27 1994-12-22 Merck & Co Inc Controlled release drug delivery device comprising a core and a polymeric coating which is water impermeable but contains apertures to expose the core
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
JPH06247854A (ja) * 1993-02-24 1994-09-06 Ss Pharmaceut Co Ltd アスコルビン酸含有組成物
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5976570A (en) * 1993-12-21 1999-11-02 Applied Analytical Industries, Inc. Method for preparing low dose pharmaceutical products
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
JPH10501811A (ja) * 1994-06-20 1998-02-17 シェーリング コーポレイション 低コレステロール化剤として有用な置換アゼチジノン化合物
US6268392B1 (en) * 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
MX9702175A (es) * 1994-09-20 1997-06-28 Pfizer Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
GEP20033006B (en) * 1995-10-31 2003-07-10 Schering Corp Sugar-Substituted 2-Azetidinones Useful as Hypocholesterolemic Agents
JP2000508659A (ja) * 1996-04-17 2000-07-11 メルク エンド カンパニー インコーポレーテッド 心血管疾患関連の危険性を低減する組み合わせ療法
US6673831B1 (en) 1996-04-17 2004-01-06 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
AU4228997A (en) 1996-07-09 1998-02-02 Merck & Co., Inc. Method for treating homozygous familial hypercholesterolemia
FR2751540B1 (fr) * 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
US6235706B1 (en) * 1996-09-18 2001-05-22 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6251852B1 (en) * 1996-09-18 2001-06-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6245797B1 (en) * 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
EP1089731A4 (en) 1998-06-24 2003-06-18 Merck & Co Inc COMPOSITIONS AND METHOD FOR TREATING INCREASED BLOOD CHOLESTEROL LEVELS
CA2336192A1 (en) 1998-06-24 1999-12-29 Merck & Co., Inc. Compositions and methods for treating elevated blood cholesterol
US6099865A (en) * 1998-07-08 2000-08-08 Fmc Corporation Croscarmellose taste masking
US6268352B1 (en) * 1998-09-02 2001-07-31 The Regents Of The University Of California Promoters of neural regeneration
JP2000109882A (ja) * 1998-10-01 2000-04-18 Nof Corp 油性粉末、製造方法および用途
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6207822B1 (en) * 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
EP1161236A1 (en) 1999-03-08 2001-12-12 Merck & Co., Inc. Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
AU764048B2 (en) 1999-03-08 2003-08-07 Merck & Co., Inc. Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
ES2249253T3 (es) 1999-03-10 2006-04-01 G.D. Searle Llc Metodo y composicion para administrar un inhibidor de la ciclooxigenasa-2.
JP2000302672A (ja) * 1999-04-16 2000-10-31 Taisho Pharmaceut Co Ltd 咀嚼可能な被覆錠剤
JP3732039B2 (ja) * 1999-05-21 2006-01-05 三菱化学フーズ株式会社 錠剤用組成物
UA72922C2 (uk) 1999-08-03 2005-05-16 Ліллі Айкос Ллк ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ З <font face="Symbol">b</font>-КАРБОЛІНОМ (ВАРІАНТИ) ТА СПОСІБ ЛІКУВАННЯ СЕКСУАЛЬНОЇ ДИСФУНКЦІЇ
US6328995B1 (en) * 1999-09-24 2001-12-11 Basf Aktiengesellschaft Stable vitamin and/or carotenoid products in powder form and process for their production
DE60019741T2 (de) * 1999-12-08 2006-03-02 Pharmacia Corp., Chicago Nanopartikelzusammensetzungen enthaltend eplerenon
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US6248359B1 (en) 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
BRPI0108435B8 (pt) 2000-02-29 2021-05-25 Bristol Myers Squibb Co formulação e uso de entecavir de baixa dose
AU2001288724A1 (en) * 2000-09-06 2002-03-22 Merck & Co., Inc. Dihydroxy open-acid salt of simvastatin
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CA2432798C (en) * 2000-12-20 2007-02-27 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
ES2326158T3 (es) * 2000-12-28 2009-10-02 Kissei Pharmaceutical Co., Ltd. Derivados de glucopiranosiloxipirazol y su utilizacion como medicamentos.
RS51449B (sr) 2001-01-26 2011-04-30 Schering Corporation Kombinacija aktivatora peroksizom proliferator-aktiviranog receptora (ppar) i inhibitora apsorpcije sterola i lečenje vaskularnih indikacija
CZ20032031A3 (cs) 2001-01-26 2003-12-17 Schering Corporation Farmaceutický prostředek
NZ542090A (en) 2001-01-26 2006-09-29 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
CA2434430A1 (en) 2001-01-26 2002-08-01 Harry R. Davis The use of substituted azetidinone compounds for the treatment of sitosterolemia
US20030053981A1 (en) 2001-01-26 2003-03-20 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
BRPI0208384B1 (pt) 2001-03-28 2016-05-31 Merck Sharp & Dohme síntese enantiosseletiva de compostos intermediários de azetidinona
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa

Also Published As

Publication number Publication date
KR20050045993A (ko) 2005-05-17
US20070160666A1 (en) 2007-07-12
DK1531805T3 (da) 2008-07-07
ATE393628T1 (de) 2008-05-15
PA8577901A1 (es) 2004-10-08
US7229982B2 (en) 2007-06-12
EA200500279A1 (ru) 2005-06-30
HRP20080518A2 (en) 2009-03-31
IS7637A (is) 2005-01-10
ES2303603T3 (es) 2008-08-16
EP1531805A1 (en) 2005-05-25
BR0312933A (pt) 2005-07-12
CN101069684A (zh) 2007-11-14
MY148689A (en) 2013-05-31
AU2003261217B2 (en) 2009-06-04
US7718643B2 (en) 2010-05-18
PE20050128A1 (es) 2005-03-22
TW200412944A (en) 2004-08-01
ME00008B (me) 2010-02-10
MEP30808A (en) 2010-10-10
DE60320652T2 (de) 2009-06-10
EP1531805B1 (en) 2008-04-30
US20040126423A1 (en) 2004-07-01
CN1310643C (zh) 2007-04-18
SI1531805T1 (sl) 2008-08-31
EP1992343A1 (en) 2008-11-19
HK1080384A1 (en) 2006-04-28
NZ537611A (en) 2007-04-27
RS20050061A (en) 2007-09-21
ECSP085573A (es) 2008-03-26
GT200300149AA (es) 2009-07-09
UA82489C2 (uk) 2008-04-25
PT1531805E (pt) 2008-06-19
TNSN05022A1 (en) 2007-05-14
MA27289A1 (fr) 2005-04-01
WO2004010993A1 (en) 2004-02-05
US20090253675A1 (en) 2009-10-08
AU2009200768A1 (en) 2009-03-19
ZA200500196B (en) 2006-07-26
KR20080070089A (ko) 2008-07-29
RS50419B (sr) 2009-12-31
ME00207B (me) 2011-02-10
IL191348A0 (en) 2008-11-03
PL375065A1 (en) 2005-11-14
NO20051033L (no) 2005-04-25
GEP20084443B (en) 2008-08-10
MXPA05001004A (es) 2005-05-16
ECSP055573A (es) 2005-04-18
US20080275020A1 (en) 2008-11-06
MEP4708A (xx) 2010-02-10
AU2003261217A1 (en) 2004-02-16
AR067030A2 (es) 2009-09-30
CR9767A (es) 2008-04-10
IL166279A0 (en) 2006-01-15
RS20080072A (en) 2008-11-28
JP2005538104A (ja) 2005-12-15
TW200906388A (en) 2009-02-16
CN1671376A (zh) 2005-09-21
DE60320652D1 (de) 2008-06-12
GT200300149A (es) 2004-03-04
CA2493076A1 (en) 2004-02-05
NO20082156L (no) 2005-04-25
JP2008291034A (ja) 2008-12-04
EA008888B1 (ru) 2007-08-31
HRP20050081A2 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
AR040588A1 (es) Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
BR0308613A (pt) Combinação de compostos orgânicos
MY152185A (en) Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
NO20045072L (no) Tablett med hoyt medikamentinnhold
RS52110B (en) DIPEPTIDIL PEPTIDASE INHIBITORS FOR TREATMENT OF DIABETES
HRP20090471T1 (en) Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
TW200626558A (en) Indazolone derivatives
NO20052335L (no) Dispergerbare deferacirox-tabletter
UA90742C2 (en) Pyrazolone derivatives
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
MX2007006279A (es) Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema de produccion de endotelina endogena, e inhibidores de hmg coa-reductasa.
MXPA02012160A (es) Composiciones medicinales las cuales contienen derivados de propenona.
ATE301463T1 (de) Pharmazeutische zusammensetzungen enthaltend 17alpha-furanylester von 17beta-carbothioat androstanderivaten und einen muskarinrezeptorantagonist
ATE350064T1 (de) Pharmazeutische zusammensetzungen von rapamycines
DOP2003000676A (es) Formulacion farmaceutica
TH77076B (th) สารผสมตามสูตรทางเภสัชกรรม
PE20040697A1 (es) Composicion farmaceutica que comprende un antagonista de ltb4 y un inhibidor de la cox-2 o cox-1/2 combinado
UA132547U (uk) Лікарський засіб знеболювальної та спазмолітичної дії
CO6160298A2 (es) Combinaciones farmaceuticas para el tratamiento de dispidemia acompañada de hipertension

Legal Events

Date Code Title Description
FB Suspension of granting procedure